High tech pharmaceuticals reviews

We are a clinical stage biopharmaceutical company applying our extensive knowledge of deuterium chemistry to discover and develop novel small molecule drugs. Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Our approach typically starts with approved drugs that may be improved with deuterium substitution. Our technology provides the opportunity to develop products that may compete with the non-deuterated drug in existing markets or to leverage the known activity of approved drugs to expand into new indications. Our deuterated chemical entity platform, or DCE Platform®, has broad potential across numerous therapeutic areas. The following table summarizes our clinical pipeline of product candidates. All of these candidates are small molecules being developed for oral administration.  ... More ...  

No clinical study has been performed on HydroxyElite™. These statements are based upon the active ingredients: [Bauhinia Purpurea L. (Leaf And Pod) Extract, Bacopa (Leaf) (Bacopa Monnieri) Extract, 1,3 Dimethylamylamine HCl, Cirsium Oligophyllum (Whole Plant) Extract, Rauwolscine Extract (Leaf And Root), Garcinia Cambogia Extract, Hydroxy Citric Acid.

WARNING: this product can raise your blood pressure and interfere with other drugs you may be taking. Talk to your doctor about this product.

*This product is not manufactured or distributed by . Labs.

We are a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. In 2013, we launched Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), our two novel treatments for patients with epilepsy. In addition, we are developing multiple product candidates in psychiatry to address significant unmet medical needs and market opportunities for the treatment of impulsive aggression (IA) and for the treatment of attention deficit hyperactivity disorder (ADHD). We are initially developing SPN-810 (molindone hydrochloride) to treat IA in patients who have ADHD. We subsequently plan to develop SPN-810 for the treatment of IA in other CNS diseases, such as autism, post traumatic stress disorder (PTSD), bipolar disorder, schizophrenia, and some forms of dementia. There are currently no approved products indicated for the treatment of IA.  ... More ...  

High tech pharmaceuticals reviews

high tech pharmaceuticals reviews


high tech pharmaceuticals reviewshigh tech pharmaceuticals reviewshigh tech pharmaceuticals reviewshigh tech pharmaceuticals reviewshigh tech pharmaceuticals reviews